A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?

International Journal of Cancer

Volumn 104, Issue 5, 2003, Pages 527-532

  Smalley, Keiran S M ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE; RAF PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG;

CELL ADHESION; CELL CYCLE; CELL DIFFERENTIATION; CELL GROWTH; CELL INVASION; CELL SURVIVAL; DRUG RESISTANCE; GENE MUTATION; GROWTH REGULATION; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; REGULATORY MECHANISM; SHORT SURVEY;

ANIMALS; CELL DIFFERENTIATION; CELL DIVISION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; GENES, RAS; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF;

EID: 0037400975     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10978     Document Type: Short Survey

References (120)

1. Cobb MH. MAP kinase pathways. Prog Biophys Mol Biol 1999;71:479-500.
2. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 2000;351:289-305.
3. Stokoe D, Macdonald SG, Cadwallader K, Symons M, Hancock JF. Activation of Raf as a result of recruitment to the plasma membrane. Science 1994;264:1463-7.
4. Dent P, Haser W, Haystead TA, Vincent LA, Roberts TM, Sturgill TW. Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro. Science 192;257:1404-7.
5. Crews CM, Alessandrini A, Erikson RL. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science 1992;258:478-80.
6. Kyriakis JM, App H, Zhang XF, Banerjee P, Brautigan DL, Rapp UR, Avruch J. Rafactivates MAP kinase-kinase. Nature 1992;358:417-21.
7. Lenormand P, Sardet C, Pages G, L'allemain G, Brunet A, Pouyssegur J. Growth factors induce nuclear translocation of MAP kinase (p42MAPK and p44MAPK) but not their activator MAP kinase kinase (p45MAPKK) in fibroblasts. J Cell Biol 1993;122:1079-88.
8. Treisman R. Ternary comples factors: growth factor regulated transcriptional activators. Curr Opin Genet Dev 1994;4:96-101.
9. Cowley S, Paterson H, Kemp P, Marshall CJ. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 1994;77:841-52.
10. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande Woude GF, Ahn NG. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 1994;265:966-70.
11. Smalley K, Eisen T. The involvement of p38 mitogen-activated protein kinase in the alpha-melanocyte stimulating hormone (alphaMSH)-induced melanogenic and anti-proliferative effects in B16 murine melanoma cells. FEBS Lett 2000;476:198-202.
12. Smalley KSM, Eisen T. Differentiation of human melanoma cells through p38 MAP kinase is associated with decreased retinoblastoma protein phosphorylation and cell cycle arrest. Melanoma Res 2002;12:187-92.
13. Kortylewski M, Heinrich PC, Kauffmann ME, Bohm M, MacKiewicz A, Behrmann I. Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells. Biochem J 2001;357:297-303.
14. Ge X, Fu YM, Meadows GG. U0126, a mitogen-activated protein kinase kinase inhibitor, inhibits the invasion of human A375 melanoma cells. Cancer Lett 2002;179:133-40.
15. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, Van Belle P, Elder DE, Herlyn M. Constitutive MAP kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res, in press.
16. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
17. van Elsas A, Zerp S, van der Flier S, Kruse-Wolters M, Vacca A, Ruiter DJ, Schrier P. Analysis of N-Ras mutations in human cutaneous melanoma: tumour heterogeneity detected by polymerase chain reaction/single-stranded conformation polymerism analysis. Rec Results Cancer Res 1995;139:57-67.
18. Tsao H, Zhang X, Fowlkes K, Haluska FG. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 2000;60:1800-4.
19. Carr J, MacKie RM. Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi. Br J Dermatol 1994;131:72-7.
20. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
21. Padua RA, Barrass N, Currie GA. A novel transforming gene in a human malignant melanoma cell line. Nature 1984;311:671-3.
22. Storm SM, Rapp UR. Oncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors. Toxicol Lett 1993;67:201-10.
23. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Einhom E, Gerrero R, Herlyn M, Minna J, Nicholson A, Futreal PA, Wooster R, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res, 2002;62:6997-7000.
24. van't Veer LJ, Burgering BM, Versteeg R, Boot AJ, Ruiter DJ, Osanto S, Schrier PI, Bos JL. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol 1989;7:3114-6.
25. van Elsas A, Zerp SF, van der Flier S, Krise KM, Aarnoudse C, Hayward NK, Ruiter DJ, Schrier PI. Relevance of ultraviolet-induced N-ras point mutations in development of human cutaneous melanoma. Am J Pathol 1996;149:883-93.
26. Albino AP, Sozzi G, Nanus DM, Jhanwar SC, Houghton AN. Malignant transformation of human melanocytes: induction of a complete melanoma phenotype and genotype. Oncogene 1992;7:2315-21.
27. Donatien PD, Diment SL, Boissy RE, Orlow SJ. Melanosomal and lysosomal alterations in murine melanocytes following transfection with the v-rasHa oncogene. Int J Cancer 1996;66:557-63.
28. Powell MB, Hyman P, Bell OD, Balmain A, Brown K, Alberts D, Bowden GT. Hyperpigmentation of and melanocytic hyperplasia in transgenic mice expressing the human T24 Ha-Ras gene regulated by a mouse tyrosinase promoter. Mol Carcinogen 1995;12:82-90.
29. Chin L, Pomerantz J, Polsky D, Jacobson M, Cohen C, Cordon-Cardo C, Horner JW 2nd, DePinho RA. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev 1997;11:2822-34.
30. Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, Shen Q, O'Hagan R, Pantginis J, Zhou H, Horner JW 2nd, Cordon-Cardo C, et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999;400:468-72.
31. Mattei S, Colombo MP, Melani C, Silvani A, Parmiani G, Herlyn M. Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer 1994;56:853-7.
32. Lazar-Molnar E, Hegyesi H, Toth S, Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000;12:547-54.
33. Nesbit M, Nesbit HKE, Bennett J, Andl T, Hsu M-Y, Dejesus E, McBrian M, Gupta AR, Erck SL, Herlyn M. Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes. Oncogene 1999;18:6469-76.
34. Satyamoorthy K, Li G, Vaidya B, Patel D. Herlyn M. Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and beta-catenin pathways. Cancer Res 2001;61:7318-24.
35. Englaro W, Rezzonico R, Durand-Clement M, Lallemand D, Ortonne JP, Ballotti R. Mitogen-activated protein kinase pathway and AP-1 are activated during cAMP-induced melanogenesis in B-16 melanoma cells. J Biol Chem 1995;270:24315-20.
36. Erhardt P, Troppmeir J, Rapp UR, Cooper GM. Differential regulation of Raf-1 and B-Raf and Ras-dependent activation of mitogen-activated protein kinase by cyclic AMP in PC12 cells. Mol Cell Biol 1995;15:5524-30.
37. Busca R, Abbe P, Mantoux F, Aberdam E, Peyssonnaux C, Eychene A, Ortonne JP, Ballotti R. Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes. EMBO J 2000;192:900-10.
38. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995;9:1149-63.
39. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994;78:59-66.
40. Sherr CJ. G1 phase progression: cycling on cue. Cell 1994;79:551-5.
41. Feramisco JR, Gross M, Kamata T, Rosenberg M, Sweet RW. Microinjection of the oncogene form of the human H-ras (T-24) protein results in rapid proliferation of quiescent cells. Cell 1984;38:109-17.
42. Pages G, Lenormand P, L'Allemain G, Chambard JC, Meloche S, Pouyssegur J. Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc Natl Acad Sci USA 1993;90:8319-23.
43. Welsh CF, Roovers K, Villanueva J, Liu Y, Schwartz MA, Assoian RK. Timing of cyclin D1 expression within G1 phase is controlled by Rho. Nat Cell Biol 2001;3:950-7.
44. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK41. Cell 1997;88:593-602.
45. Ridley AJ, Paterson HF, Noble M, Land H. Ras-mediated cell cycle arrest is altered by nuclear oncogenes to induce Schwann cell transformation. EMBO J 1998:7:1635-45.
46. Sewing A, Wiseman B, Lloyd AC, Land H. High-intensity Raf signal causes cell cycle arrest mediated by p21Cip. Mol Cell Biol 1997;17:5588-97.
47. Woods D, Parry D, Cherwinski H, Bosch E, Lees E, McMahon M. Raf-induced proliferation of cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol 1997;17:5598-611.
48. Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, Lowe SW. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 1998;12:3008-19.
49. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
50. Papp T, Jafari M, Schiffmann D. Lack of p53 mutations and loss of heterozygosity in non-cultured human melanocytic lesions. J Cancer Res Clin Oncol 1996;122:541-8.
51. Lubbe J, Reichel M, Burg G, Kleihues P. Absence of p53 gene mutations in cutaneous melanoma. J Invest Dermatol 1994;102:819-21.
52. FitzGerald MG, Harkin DP, Silva-Arrieta S, MacDonald DJ, Lucchina LC, Unsal H, O'Neill E, Koh J, Finkelstein DM, Isselbacher KJ. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci USA 1996;93;8541-5.
53. Herlyn M, Satyamoorthy K. Activated Ras: yet another player in melanoma? Am J Pathol 1996;149:739-44.
54. Sviderskaya EV, Hill SP, Evans-Whipp TJ, Chin L, Orlow SJ, Easty DJ, Cheong SC, Beach D, DePinho RA, Bennett DC. p16(Ink4a) in melanocyte senescence and differentiation. J Natl Cancer Inst 2002;94:446-54.
55. Sharpless NE, DePinho RA. The INK4A/ARF locus and its two gene products. Curr Opin Genet Dev 1999;9:22-30.
56. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
57. Imokawa G, Yada Y, Kimura M, Signalling mechanisms of endothelin-induced mitogenesis and melanogenesis in human melanocytes. Biochem J 1996;314:305-12.
58. Imokawa G, Kobayasi T, Miyagishi M. Intracellular signaling mechanisms leading to synergistic effects of endothelin-1 and stem cell factor on proliferation of cultured human melanocytes. Cross-talk via transactivation of the tyrosine kinase c-kit receptor. J Biol Chem 2000;275:33321-8.
59. Tada A, Pereira E, Beitner-Johnson D, Kavanagh R, Abdel-Malek ZA. Mitogen- and ultraviolet-B-induced signaling pathways in normal human melanocytes. J Invest Dermatol 2002;118:316-22.
60. Gana-Weisz M, Haklai R, Marciano D, Egozi Y, Ben-Baruch G, Kloog Y. The Ras antagonist S-famesylthiosalicylic acid induces inhibition of MAPK activation. Biochem Biophys Res Comm 1997;239:900-4.
61. Jansen B, Schlagbauer-Wadl H, Kahr H, Heere-Ress E, Mayer BX, Eichler H-G, Pehamberger H, Gana-Weisz M, Ben-David E, Kloog Y, Wolff K. Novel Ras antagonist blocks human melanoma growth. Proc Natl Acad Sci USA 1999;96:14019-24.
62. Smalley KSM, Eisen TG. Farnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and pro-apoptotic effects. Int J Cancer 2002;98:514-22.
63. Smalley KSM, Eisen TG. The farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. Int J Cancer, in press.
64. Pawelek J, Sansone M, Koch N, Christie G, Halaban R, Hendee J, Lemer AB, Varga JM. Melanoma cells resistant to inhibition of growth by melanocyte stimulating hormone. Proc Natl Acad Sci USA 1975;72:951-5.
65. Medrano EE, Im S, Yang F, Abdel-Malek ZA. Ultraviolet B light induces G1 arrest in human melanocytes by prolonged inhibition of retinoblastoma protein phosphorylation associated with long-term expression of the p21Waf-1/SDI-1/Cip-1 protein. Cancer Res 1995;55:4047-52.
66. Hunt G, Donatien PD, Lunec J, Todd C, Kyne S, Thody AJ. Cultured human melanocytes respond to MSH peptides and ACTH. Pigment Cell Res 1994;7:217-21.
67. Busca R, Bertolotto C, Ortonne JP, Ballotti R. Inhibition of the phosphatidylinositol 3-kinase/p70(S6)-kinase pathway induces B16 melanoma cell differentiation. J Biol Chem 1996;271:31824-30.
68. Wong G, Pawelek J, Sansome M, Morowitz J. Response of mouse melanoma cells to melanocyte stimulating hormone. Nature 1974;248:351-4.
69. Abdel-Malek Z, Swope VB, Suzuki I, Akcali C, Harriger MD, Boyce ST, Urabe K, Hearing VJ. Mitogenic and melanogenic stimulation of normal human melanocytes by melanotropic peptides. Proc Natl Acad Sci USA 1995;92:1789-93.
70. Bertolotto C, Abbe P, Hemesath TJ, Bille K, Fisher DE, Ortonne JP, Ballotti R. Microphthalmia gene product as a signal transducer in cAMP-induced differentiation of melanocytes. J Cell Biol 1998;142:827-35.
71. Dugan LL, Kim JS, Zhang Y, Bart RD, Sun Y, Holtzman DM, Gutmann DH. Differential effects of cAMP in neurons and astrocytes. J Biol Chem 1999;274:25842-8.
72. Dumaz N, Light Y, Marais R. Cyclic AMP blocks cell growth through Raf-1 dependent and Raf-1 and independent mechanisms. Mol Cell Biol 2002;22:3717-28.
73. Goding CR. Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage. Genes Dev 2000;14:1712-28.
74. Yanase H, Ando H, Horikawa M, Watanabe M, Mori T, Matsuda N. Possible involvement of ERK 1/2 in UVA-induced melanogenesis in cultured normal human epidermal melanocytes Pigment Cell Res 2001;14:103-9.
75. Wu M, Hemesath TJ, Takemoto CM, Horstmann MA, Wells AG, Price ER, Fisher DZ, Fisher DE. c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi, Genes Dev 2000;14:301-12.
76. Hemesath TJ, Price ER, Takemoto C, Badalian T, Fisher DE. MAP kinase linkes the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature 1998;391:298-301.
77. Englaro W, Bertolotto C, Busca R, Brunet A, Pages G, Ortonne J-P, Ballotti R. Inhibition of the mitogen activated protein kinase pathway triggers B16 melanoma cell differentiation. J Biol Chem 1998;273:9966-70.
78. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995;80:179-85.
79. Lerner AB, Shiohara T, Boissy RE, Jacobson KA, Lamoreux ML, Moellmann GE. A mouse model for vitiligo. J Invest Dermatol 1986;87:299-304.
80. Hughes AE, Newton VE, Liu XZ, Read AP. A gene for Waardenburg syndrome type 2 maps close to the human homologue of the human micropthalmia gene at chromosome 3p12-p141. Nat Genet 1994;7:509-512.
81. Price ER, Fisher DE. Sensorineural deafness and pigmentation genes: melanocytes and the Mitf transcriptional network. Neuron 2001;30:15-8.
82. McGill GG, Horstmann M, Widlund HR, Du J, Motyckova G, Nishimura EK, Lin Y-L, Ramaswamy S, Avery W, Ding H-F, Jordan SA, Jackson IJ, et al. Bc12 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 2002;109:707-18.
83. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 1997;275:1790-2.
84. Rimm DL, Caca K, Hu G, Harrison FB, Fearon ER. Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am J Pathol 1999;154:325-9.
85. Widlund HR, Horstmann MA, Price ER, Cui J, Lessnick SL, Wu M, He X, Fisher DE. β-catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor. J Cell Biol 2002;158:1079-87.
86. Koo HM, VanBrocklin M, McWilliams MJ, Leppla SH, Duesbery NS, Woude GF. Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proc Natl Acad Sci USA 2002;99:3052-7.
87. Eberle J, Fecker LF, Orfanos CE, Geilen CC. Endothelin-1 decreases basic apoptotic rates in human melanoma cell lines. J Invest Dermatol 2002;119:549-55.
88. Mandic A, Viktorsson K, Heiden T, Hansson J, Shoshan MC. The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis. Melanoma Res 2001;11:11-9.
89. Puyraimond A, Weitzman JB, Babiole E, Menashi S. Examining the relationship between the gelatinolytic balance and the invasive capacity of endothelial cells. J Cell Sci 1999;112:1283-90.
90. MacDougall JR, Bani MR, Lin Y, Muschel RJ, Kerbel RS. 'Proteolytic switching': opposite patterns of regulation of gelatinase B and its inhibitor TIMP-1 during human melanoma progression and consequences of gelatinase B overexpression. Br J Cancer 1999;80:504-12.
91. Vaisanen A, Kallioinen M, von Dickhoff K, Laatikainen L, Hoyhtya M, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) immunoreactive protein - a new prognostic marker in uveal melanoma? J Pathol 1999;188:56-62.
92. Aguirre Ghiso JA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 1999;147:89-104.
93. Santibanez JF, Iglesias M, Frontelo P, Martinez J, Quintanilla M. Involvement of the Ras/MAPK signaling pathway in the modulation of urokinase production and cellular invasiveness by transforming growth factor-beta(1) in transformed keratinocytes. Biochem Biophys Res Commun 2000;273:521-7.
94. Genersch E, Hayess K, Neuenfeld Y, Haller H. Sustained ERK phosphorylation is necessary but not sufficient for MMP-9 regulation in endothelial cells: involvement of Ras-dependent and -independent pathways. J Cell Sci 2000;113:4319-30.
95. Benbow U, Tower GB, Wyatt CA, Buttice G, Brinckerhoff CE. High levels of MMP-1 expression in the absence of the 2G single nucleotide polymorphism is mediated by p38 and ERK 1/2 mitogen-activated kinase in VMM5 melanoma cells. J Cell Biochem 2002;86:307-19.
96. Tower GB, Coon CC, Benbow U, Vinceti MP, Brinckerhoff CE. Erk1/2 differentially regulates expression from the 1G/2G single nucleotide polymorphisms in melanoma cells. Biochim Biophys Acta 2002;1586:265-74.
97. Denkert C, Siegert A, Leclere A, Turzynski A, Hauptmann S. An inhibitor of stress-activated MAP-kinases reduces invasion and MMP-2 expression of malignant melanoma cells. Clin Exp Metastasis 2002;19:79-85.
98. Schwartz MA, Schaller MD, Ginsberg MH. Integrins: emerging paradigms of signal transduction. Ann Rev Cell Biol 1995;11:549-99.
99. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25.
100. Montgomery AM, Reisfeld RA, Cheresh DA. Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci USA 1994;91:8856-60.
101. Petitclerc E, Stromblad S, von Schalscha TL, Mitjans F, Piulats J, Montgomery AM, Cheresh DA, Brooks PC. Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res 1999;59:2724-30.
102. Albelda SM, Mette SA, Elder DE, Stewart DE, Stewart R, Damjanovich L, Herlyn M. Buck CA. Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumour progression. Cancer Res 1990;50:6757-64.
103. Felding-Habermann B, Ruggeri ZM, Cheresh DA. Distinct biological consequences of integrin alpha v beta 3-mediated melanoma cell adhesion to fibrinogen and its plasmic fragments. J Biol Chem 1992;267:5070-7.
104. Seftor RE. Role of the beta3 integrin subunit in human primary melanoma progression: multifunctional activities associated with alpha(v)beta3 integrin expression. Am J Pathol 1998;153:1347-51.
105. Li XB, Chen B, Blystone SD, McHugh KP, Ross FP, Ramos DM. Differential expression of alphaV integrins in K1735 melanoma cells. Invas Metastasis 1998;18:1-14.
106. Natali PG, Nicotra MR, Bartolazzi A, Cavaliere R, Bigotti A. Integrin expression in cutaneous malignant melanoma: association of the alpha 3/beta 1 heterodimer with tumor progression. Int J Cancer 1993;54:68-72.
107. Schumacher D, Schaumburg-Lever G. Ultrastructural localization of alpha-3 integrin subunit in malignant melanoma and adjacent epidermis. J Cutan Pathol 1999;26:321-6.
108. Melchiori A, Mortarini R, Carlone S, Marchisio PC, Anichini A, Noonan DM, Albini A. The alpha 3 beta 1 integrin is involved in melanoma cell migration and invasion. Exp Cell Res 1995;219:233-42.
109. Woods D, Cherwinski H, Venetsanakos E, Bhat A, Gysin S, Humbert M, Bray PF, Saylor VL, McMahon M. Induction of beta3-integrin gene expression by sustained activation of the Ras-regulated RafMEK-extracellular signal-regulated kinase signaling pathway. Mol Cell Biol 2001;21:3192-205.
110. Tang A, Eller MS, Hara M, Yaar M, Hirohashi S, Gilchrest BA. E-cadherin is the major mediator of human melanocyte adhesion to keratinocytes in vitro. J Cell Sci 1994;107:983-92.
111. Danen EH, de Vries TJ, Morandini R, Ghanem GG, Ruiter DJ, van Muijen GN. E-cadherin expression in human melanoma. Melan Res 1996;6:127-31.
112. Scott GA, Cassidy L. Rac1 mediates dendrite formation in response to melanocyte stimulating hormone and ultraviolet light in a murine melanoma model. J Invest Dermatol 1998;111:243-50.
113. Li G, Schaider H, Satyamoorthy K, Hanakawa Y, Hashimoto K, Herlyn M. Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene 2001;20:8125-35.
114. Wilson D, Alessandrini A. MEK1 activation rescues Jurkat T cells from Fas-induced apoptosis. Cell Immunol 1999;194:67-77.
115. Stadheim K, Kuvera G. Extracellular signal related kinase (ERK) activity is required for TPA-mediated inhibition of drug-induced apoptosis. Biochem Biophys Res Commun 1998;245:266-71.
116. Persons DL, Yazlovitskaya EM, Cui W, Pelling JC. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res 1999;5:1007-14.
117. Mitsui H, Takuwa N, Maruyama T, Maekawa H, Hirayama M, Sawatari T, Hashimoto N, Takuwa Y, Kimura S. The MEK1-ERK map kinase pathway and the PI 3-kinase-Akt pathway independently mediate anti-apoptotic signals in HepG2 liver cancer cells. Int J Cancer 2001;92:55-62.
118. Jansen B, Schlagbauer-Wadl H, Eichler HG, Wolff K, van Elsas A, Schrier PI, Pehamberger H. Activated N-ras contributes to the chemoresistance of human melanoma in severe combined immunodeficiency (SCID) mice by blocking apoptosis. Cancer Res 1997;57:362-5.
119. Pomp J, Ouwerkerk IJ, Hoogstraten C, Wondergem J, Davelaar J, Leer JW, Schrier PI. The influence of the oncogene N-Ras on cell cycle delay in a human melanoma cell line with reduced radioresistance. Oncol Rep 2000;7:663-667.
120. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, CordonCardo C, Lowe SW. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001;409:207-11.